The present disclosure is related to the use of an organic extract of Ageratina pichinchensis standardized by the content of its active compounds, taraxerol and encecalin, in the preparation of a pharmaceutical composition, useful in the treatment or prevention of vulvovaginitis caused by Candida albicans (vaginal candidiasis). The present invention demonstrates the efficacy and clinical and therapeutic safety of a phytopharmaceutical in the form of an ovuli made with hexane-ethyl acetate extract from Ageratina pichinchensis at a concentration of 7% in patients with a clinical picture of vaginal candidiasis.
展开▼
